![](/img/cover-not-exists.png)
PG18 A COST-EFFECTIVENESS EVALUATION—RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
CJ Gibbons, J Morris, AK O'SullivanVolume:
11
Year:
2008
Language:
english
DOI:
10.1016/s1098-3015(10)66722-8
File:
PDF, 78 KB
english, 2008